Identification
- Generic Name
- Peptide YY (3-36)
- DrugBank Accession Number
- DB05004
- Background
Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.
- Type
- Small Molecule
- Groups
- Investigational
- Synonyms
- Pyy (3-36) peptide
- PYY 3-36
- PYY(3-36)
- PYY3-36
- External IDs
- AC162352
- GT-001
Pharmacology
- Indication
Investigated for use/treatment in metabolic disease and obesity.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
PYY 3-36 acts via the presynaptic Y2 receptor in the ARC. It decreases neuropeptide Y (NPY) release from static hypothalamic explants and thus acts to decrease food intake.
Target Actions Organism UNeuropeptide Y receptor type 2 Not Available Humans UNeuropeptide Y receptor type 1 Not Available Humans UNeuropeptide Y receptor type 5 Not Available Humans UNeuropeptide Y receptor type 4 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 7PQZ90ULIR
- CAS number
- 123583-37-9
References
- General References
- Chandarana K, Batterham R: Peptide YY. Curr Opin Endocrinol Diabetes Obes. 2008 Feb;15(1):65-72. doi: 10.1097/MED.0b013e3282f3f4b1. [Article]
- Sloth B, Davidsen L, Holst JJ, Flint A, Astrup A: Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. Am J Physiol Endocrinol Metab. 2007 Aug;293(2):E604-9. Epub 2007 Jun 12. [Article]
- External Links
- PubChem Substance
- 347909887
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Obesity (Disorder) 1 1 Completed Treatment Feeding and Eating Disorders 1 1 Completed Treatment Healthy Subjects (HS) 1 0 Completed Basic Science Healthy Subjects (HS) 1 Not Available Completed Treatment Obesity (Disorder) 1 Not Available Not Yet Recruiting Not Available Obesity (Disorder) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Receptor activity
- Specific Function
- Receptor for neuropeptide Y and peptide YY. The rank order of affinity of this receptor for pancreatic polypeptides is PYY > NPY > PYY (3-36) > NPY (2-36) > [Ile-31, Gln-34] PP > [Leu-31, Pro-34] N...
- Gene Name
- NPY2R
- Uniprot ID
- P49146
- Uniprot Name
- Neuropeptide Y receptor type 2
- Molecular Weight
- 42730.69 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Peptide yy receptor activity
- Specific Function
- Receptor for neuropeptide Y and peptide YY. The rank order of affinity of this receptor for pancreatic polypeptides is NPY > [Pro-34] PYY, PYY and [Leu-31, Pro-34] NPY > NPY (2-36) > [Ile-31, Gln-3...
- Gene Name
- NPY1R
- Uniprot ID
- P25929
- Uniprot Name
- Neuropeptide Y receptor type 1
- Molecular Weight
- 44391.535 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Peptide yy receptor activity
- Specific Function
- Receptor for neuropeptide Y and peptide YY. The activity of this receptor is mediated by G proteins that inhibit adenylate cyclase activity. Seems to be associated with food intake. Could be involv...
- Gene Name
- NPY5R
- Uniprot ID
- Q15761
- Uniprot Name
- Neuropeptide Y receptor type 5
- Molecular Weight
- 50725.99 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Peptide yy receptor activity
- Specific Function
- Receptor for neuropeptide Y and peptide YY. The rank order of affinity of this receptor for pancreatic polypeptides is PP, PP (2-36) and [Ile-31, Gln-34] PP > [Pro-34] PYY > PYY and [Leu-31, Pro-34...
- Gene Name
- NPY4R
- Uniprot ID
- P50391
- Uniprot Name
- Neuropeptide Y receptor type 4
- Molecular Weight
- 42194.55 Da
Drug created at October 21, 2007 22:23 / Updated at June 12, 2020 16:52